- Home
- SGN vs VYNE Comparison
SGN vs VYNE Comparison
Compare SGN & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- VYNE
- Stock Information
- Founded
- SGN 2019
- VYNE 2003
- Country
- SGN United States
- VYNE United States
- Employees
- SGN N/A
- VYNE N/A
- Industry
- SGN
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- SGN
- VYNE Health Care
- Exchange
- SGN Nasdaq
- VYNE Nasdaq
- Market Cap
- SGN 7.8M
- VYNE 7.9M
- IPO Year
- SGN 2023
- VYNE 2018
- Fundamental
- Price
- SGN $1.75
- VYNE $0.41
- Analyst Decision
- SGN
- VYNE Buy
- Analyst Count
- SGN 0
- VYNE 2
- Target Price
- SGN N/A
- VYNE $8.00
- AVG Volume (30 Days)
- SGN 308.0K
- VYNE 3.1M
- Earning Date
- SGN 11-13-2025
- VYNE 11-06-2025
- Dividend Yield
- SGN N/A
- VYNE N/A
- EPS Growth
- SGN N/A
- VYNE N/A
- EPS
- SGN N/A
- VYNE N/A
- Revenue
- SGN $391,126.00
- VYNE $476,000.00
- Revenue This Year
- SGN N/A
- VYNE N/A
- Revenue Next Year
- SGN N/A
- VYNE N/A
- P/E Ratio
- SGN N/A
- VYNE N/A
- Revenue Growth
- SGN N/A
- VYNE N/A
- 52 Week Low
- SGN $0.44
- VYNE $0.28
- 52 Week High
- SGN $13.72
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- SGN 46.22
- VYNE 56.68
- Support Level
- SGN $1.67
- VYNE $0.32
- Resistance Level
- SGN $2.08
- VYNE $0.46
- Average True Range (ATR)
- SGN 0.14
- VYNE 0.03
- MACD
- SGN -0.03
- VYNE 0.02
- Stochastic Oscillator
- SGN 8.67
- VYNE 72.20
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.